Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change

JAMA Neurology

Volumn 73, Issue 6, 2016, Pages 698-705

  Soldan, Anja ^a   Pettigrew, Corinne ^a   Cai, Qing ^b   Wang, Mei Cheng ^b   Moghekar, Abhay R ^a   O'Brien, Richard J ^c   Selnes, Ola A ^a   Albert, Marilyn S ^a   Rodzon, Barbara ^d   Gottesman, Rebecca ^d   Sacktor, Ned ^d   McKhann, Guy ^d   Turner, Scott ^d   Farrington, Leonie ^d   Grega, Maura ^d   Rudow, Gay ^d   D'Agostino, Daniel ^d   Rudow, Scott ^d   Miller, Michael ^d   Mori, Susumu ^d   Ratnanather, Tilak ^d   Brown, Timothy ^d   Chi, Hayan ^d   Kolasny, Anthony ^d   Oishi, Kenichi ^d   Reigel, Thomas ^d   Younes, Laurent ^d   Spangler, Abby ^d   Scherer, Roberta ^d   Shade, David ^d   Ervin, Ann ^d   Jones, Jennifer ^d   Toepfner, Matt ^d   Parlett, Lauren ^d   Patterson, April ^d   Mohammed, Aisha ^d   Lu, Daisy ^d   Troncoso, Juan ^d   Crain, Barbara ^d   Pletnikova, Olga ^d   Fisher, Karentmr ^d   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; PHOSPHOPROTEIN; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; PEPTIDE FRAGMENT;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SEX; STAGING; TIME; CEREBROSPINAL FLUID; COGNITION DISORDERS; COMPLICATION; DISEASE COURSE; GENETICS; MENTAL HEALTH; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; COGNITION DISORDERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; TAU PROTEINS; YOUNG ADULT;

EID: 84974602452     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.0194     Document Type: Article

References (41)

1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Associationworkgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
2. Desikan RS, Cabral HJ, Hess CP, et al; Alzheimer's Disease Neuroimaging Initiative. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain. 2009; 132(pt 8):2048-2057.
3. GrotheMJ, Heinsen H, Amaro E Jr, Grinberg LT, Teipel SJ; Alzheimer's Disease Neuroimaging Initiative. Cognitive correlates of basal forebrain atrophy and associated cortical hypometabolism in mild cognitive impairment [published online April 2, 2015]. Cereb Cortex.
4. Pagani M, De Carli F, Morbelli S, et al. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls: a European Alzheimer's Disease Consortium (EADC) study. Neuroimage Clin. 2015;7:34-42.
5. Jack CR Jr, Knopman DS,Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71 (6):765-775.
6. Holtzman DM. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging. 2011;32(suppl 1):S4-S9.
7. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382-389.
8. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.
9. Mormino EC, Betensky RA, Hedden T, et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMANeurol. 2014;71(11):1379-1385.
10. Wirth M, Oh H, Mormino EC, Markley C, Landau SM, JagustWJ. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement. 2013;9(6):687-698.e1. doi:10.1016/j.jalz.2012.10.012.
11. Doraiswamy PM, Sperling RA, Johnson K, et al; AV45-A11 Study Group. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19(9):1044-1051.
12. Mormino EC, Betensky RA, Hedden T, et al; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study. Amyloid and APOE ϵ4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767.
13. Donohue MC, Sperling RA, Salmon DP, et al; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer's Disease Neuroimaging Initiative; Alzheimer's Disease Cooperative Study. The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970.
14. Vemuri P, Lesnick TG, Przybelski SA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain. 2015;138(pt 3):761-771.
15. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013; 80(19):1784-1791.
16. Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC. CSF biomarkers of Alzheimer disease: "noncognitive" outcomes. Neurology. 2013;81(23): 2028-2031.
17. Li G,Millard SP, Peskind ER, et al. Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. JAMA Neurol. 2014;71(6):742-751.
18. Glodzik L, de Santi S, Tsui WH, et al. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging. 2011;32(12):2131-2141.
19. Aschenbrenner AJ, Balota DA, Fagan AM, Duchek JM, Benzinger TL, Morris JC. Alzheimer disease cerebrospinal fluid biomarkers moderate baseline differences and predict longitudinal change in attentional control and episodic memory composites in the Adult Children Study. J Int Neuropsychol Soc. 2015;21(8):573-583.
20. Insel PS, Mattsson N, Mackin RS, et al; Alzheimer's Disease Neuroimaging Initiative. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol. 2015;2(5):534-547.
21. Corder EH, Saunders AM, StrittmatterWJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923.
22. AlbertM, Soldan A, Gottesman R, et al. Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. Curr Alzheimer Res. 2014;11(8): 773-784.
23. AlbertMS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
24. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
25. Moghekar A, Goh J, Li M, AlbertM, O'Brien RJ. Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. Arch Neurol. 2012;69(2): 246-250.
26. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7 (2):180-184.
27. Morris JC, Roe CM, Xiong C, et al. APOE predicts Aβ but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131.
28. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825.
29. Rowe CC, Ellis KA, RimajovaM, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.
30. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844.
31. Hulette CM,Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57(12):1168-1174.
32. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62(11):1087-1095.
33. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.
34. Jack CR Jr,Wiste HJ,Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20):1732-1740.
35. Knopman DS, Jack CR Jr,Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol. 2013;73(4):472-480.
36. Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, JagustWJ. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals. J Neurosci. 2013;33(13):5553-5563.
37. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol. 2011;68(8):1062-1064.
38. Resnick SM, Bilgel M, Moghekar A, et al. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiol Aging. 2015;36(8):2333-2339.
39. Khachaturian AS, Corcoran CD,Mayer LS, Zandi PP, Breitner JC; Cache County Study Investigators. Apolipoprotein E ϵ4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch Gen Psychiatry. 2004;61(5):518-524.
40. Roe CM, Fagan AM, Grant EA, et al. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Arch Neurol. 2011;68 (9):1145-1151.
41. Soldan A, Pettigrew C, Li S, et al; BIOCARD Research Team. Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. Neurobiol Aging. 2013;34(12):2827-2834.